Skip to main content

Published locations for FDA expands tenofovir alafenamide (Vemlidy) use to adolescents with chronic HBV

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA expands tenofovir alafenamide (Vemlidy) use to adolescents with chronic HBV

User login

  • Reset your password
  • /content/fda-expands-tenofovir-alafenamide-vemlidy-use-adolescents-chronic-hbv
  • /clinicianreviews/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /familypracticenews/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /gihepnews/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use-adolescents
  • /idpractitioner/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /internalmedicinenews/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /pediatricnews/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /pediatrics/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use-adolescents
  • /infectiousdisease/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /internalmedicine/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use
  • /familymedicine/article/259234/gastroenterology/fda-expands-tenofovir-alafenamide-vemlidy-use